Taken together, these results indicate that S100P and SPP1 are two optimal biomarkers for distinguishing iCCAphl and iCCApps, which can effectively divide the iCCA patients into two subtypes with different cell origins and clinicopathological characteristics. The gene discussed is SPP1; the disease is infantile convulsions and choreoathetosis.